- Completed Cohort 2 enrollment in ASPIRO, the Phase 1/2 clinical study of AT132 for the treatment of X-linked Myotubular Myopathy
- Plan interactions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in Q4 2018 to discuss development plans and the potential registration pathway for AT132
PR Newswire
SAN FRANCISCO, Nov. 6, 2018